Sero prevalence of SARS-CoV-2 in general population of Nagpur district

Sarita K. Sharma, Pragati G. Rathod, Ujwala U. Ukey, Uday W. Narlawar, Sanjay Zodpey


Background: Population based sero-epidemiological studies help us to determine the burden of COVID-19 infection at the community level and to monitor the trends in transmission of SARS-CoV-2 infection. Antibody based sero-positivity indicates the extent of spread of infection in the given population and forms the basis for strengthening public health mitigation measures. The present study was carried out with the objective of conducting population level serosurvey in Nagpur district to understand the spread of SARS-CoV-2 and to help the designing and implementation of appropriate health system and policy level interventions. This cross-sectional study was carried out in Nagpur District over two weeks in October and November 2020. For the purpose of this survey the Nagpur district was divided into NMC area and Non NMC area.

Methods: House to house survey was carried out and data was collected using Google form. For detection of SARS-CoV-2 specific antibodies venous blood was collected from each participant and electrochemiluminescence immunoassay was performed. The data was cleaned, coded and analysed using EPI INFO.

Results: The total seroprevalence in Nagpur district was found to be 35.17 %. The seroprevalance in NMC area was 49.7% which was more than twice from that of Non NMC area (20.7%).

Conclusions: Considerably large numbers of infections are asymptomatic, however a sizeable proportion of population is still susceptible to the infection and thus there is no time for complacency.


Seroprevalence, Serosurvey, COVID-19, General population

Full Text:



Turabian JL. Medical concepts with clinical-epidemiological implications that have to be re-assessed since the corona virus disease 2019 (Covid-19) Pandemic. Int J General Practice. 2020;1:17-27.

Turabian JL. Clinical-epidemiological characteristics that may help the general practitioner to consider Covid-19 diagnosis in acute respiratory infections when diagnostic tests are not accessible. Epidemol Int J. 2020;4:143-8.

Research and analysis Sero-surveillance of COVID-19. Available at: publications/national-covid-19-surveillance-reports/sero-surveillance-of-covid-19. Accessed on 03 March 2020.

Hsueh PR, Kao CL, Lee CN, Chen LK , Ho MS, Sia C, et al. SARS Antibody Test for Serosurveillance. Emerg Infect Dis. 2004;10:1558-62.

Covid-19 Serosurveillance. The map and the territory. Available at: map_and_the_territory. Accessed on 03 March 2020.

Jardine A, Deeks SL, Patel MS, Menzies RI, Gilbert GL, McIntyre PB. An evaluation of the Australian National Serosurveillance Program. CDI. 2010;34:29-36.

Kumar MS, Bhatnagar T, Manickam P, Kumar VS, Rade K, Shah N, et al. National sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India: Protocol for community-based surveillance. Indian J Med Res. 2020;151:419- 23. 2020. Available at: Accessed on 03 March 2020.

Khan SMS, Qurieshi MA, Haq I, Majid S, Bhat AA, Nabi S, et al. Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India -A cross-sectional study. PLoS ONE. 2020;15:e0239303.

Ahmedabad: sero-survey suggests nearly one in four has covid antibodies. Available at: https://www. Accessed on 03 March 2020.

Dixit JV, Iravane J, Andurkar SP, Gandal U, Padalkar N, Sayyed M, et al. Seroprevalence of COVID-19 in Aurangabad district. IJCRT. 2020;8: 3675-83.

Banaji M. What Do the Delhi and Mumbai Sero-Survey Results Tell Us About COVID-19 in India? - The Wire Science. Available at: https://science.the Accessed on 03 March 2020.

29% have antibodies in 2nd Delhi sero survey, up from 23% last month. The Indian Express. Available at: Accessed on 03 March 2020.

Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396:313-9.

Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020;180:1576 -86.

Polla´n M, Pe´rez-Go´mez B, Pastor-Barriuso R, Oteo J, Herna´n MA, Pe´rez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396:535-44.

Shakiba M, Nazemipour M, Salari A, Mehrabian F, Nazari SH, Rezvani S, et al. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. Emerg Infect Dis. 2021;27:636-8.

Doi A, Iwata K, Kuroda H, Hasuike T, Nasu S, Kanda A, et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study. Infect Dis. 2020;2020:20079822.

Snoeck CJ, Vaillant M, Abdelrahman T, Satagopam VP, Turner JD, Beaumont K, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population the CON-VINCE study. Medrxiv. 2020; 2020:20092916.

Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2- Specific antibodies among adults in Los Angeles County, California, on April 10–11, 2020. JAMA. 2020;2020:8279.